Increased glycolytic substrate protection improves ischemic cardiac dysfunction and reduces injury.
Early clinical trials of glucose-insulin-potassium for acute myocardial infarction were inconclusive. However, several recent placebo-controlled, prospective, randomized clinical trials of glucose-insulin-potassium for acute myocardial infarction or metabolic support during and after cardiac surgery have demonstrated its efficacy. These clinical results are supported by experimental studies that have shown a strong protective effect of increased glycolytic substrate on ischemic myocardium in concert with an improved bioenergetic status.
Apstein
C S
CS
Cardiac Muscle Research Laboratory, Boston University School of Medicine, MA 02118, USA. capstein@bu.edu
D000244:Adenosine Diphosphate / Q000378:metabolism; D000818:Animals; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D005947:Glucose / Q000378:metabolism / Q000627:therapeutic use; D006019:Glycolysis / Q000502:physiology*; D006801:Humans; D007328:Insulin / Q000378:metabolism / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000378:metabolism / Q000517:prevention & control*; D015428:Myocardial Reperfusion Injury / Q000378:metabolism / Q000517:prevention & control*; D009206:Myocardium / Q000378:metabolism*; D010085:Oxidative Phosphorylation; D010101:Oxygen Consumption; D011188:Potassium / Q000378:metabolism / Q000627:therapeutic use
D005230:Fatty Acids, Nonesterified; D007328:Insulin; D000244:Adenosine Diphosphate; D005947:Glucose; D011188:Potassium